Ademi LLP opens fiduciary probe into NextCure's deal with Avere Therapeutics
Milwaukee law firm Ademi LLP has opened an investigation into NextCure (NASDAQ: NXTC), examining whether the biotech's recently announced transaction with Avere Therapeutics delivers a fair price to public shareholders.…
Filed via prnewswire.com